Gasthuiszusters Antwerpen

The cardiology department at Gasthuiszusters Antwerpen is conducting research focused on atrial fibrillation and the prevention of stroke or systemic embolism. Current studies aim to evaluate a new oral anticoagulant compared with established therapy, assessing both efficacy in reducing clot‑related events and overall bleeding risk.

• Evaluation of innovative anticoagulant strategies for stroke prevention
• Comparative safety analysis with standard treatment options
• Optimization of risk‑benefit balance in patients at high thrombotic risk

These trials seek to improve outcomes for individuals with irregular heart rhythms by offering potentially safer and more effective prevention methods, reinforcing the site’s commitment to advancing cardiovascular care.

In the oncology‑focused arm of the cardiology department, investigators are studying the continued use and safety profile of darolutamide in patients with advanced prostate cancer. The research evaluates long‑term tolerability and aims to confirm that ongoing treatment remains beneficial without unexpected adverse effects.

• Long‑term safety monitoring of targeted cancer therapy
• Assessment of treatment continuation outcomes in prostate malignancy
• Identification of any emerging safety signals during extended use

By focusing on both efficacy and patient safety, the site contributes valuable data that may shape future standards for managing neoplastic diseases.